Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | PLA2G4B | P0C869 | 7/20 | 0.56 |
| ▸ | ALAD | P13716 | 2/20 | 0.51 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15177390 | 0.90 | RARB (0.57) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL13246820 | 0.86 | RARB (0.53) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL11655342 | 0.83 | PLA2G2A (0.58) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL11721300 | 0.83 | PLA2G2A (0.58) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL2493280 | 0.81 | ALAD (0.50) | RARBALADPTPN11 | |
| SCHEMBL4185457 | 0.79 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL5828640 | 0.79 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL5858775 | 0.79 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL8532269 | 0.79 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL8943017 | 0.79 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2674437-A1 | Novel antibacterial agents for the treatment of GRAM positive infections | Cubist Pharmaceuticals, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-2379580-B1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARM INC (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8507647-B2 | Antibacterial agents for the treatment of gram positive infections | CUBIST PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507647-B2 | Antibacterial agents for the treatment of gram positive infections | CUBIST PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507647-B2 | Antibacterial agents for the treatment of gram positive infections | CUBIST PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2379580-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | Cubist Pharmaceuticals, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2010075215-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | RARB 4537/4885TP53 4408/4885TSHR 4677/4885 |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | RARB 4537/4885TP53 4408/4885TSHR 4677/4885 |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | RARB 4537/4885TP53 4408/4885TSHR 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.